ArticleBMJ global health2026
Pre-exposure prophylaxis (PrEP) for men who have sex with men and transgender women in a clinic and a community-based setting: results from the first demonstration project in India.
Article in BMJ global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding the 'real-world' challenges of delivery of pre-exposure prophylaxis (PrEP) among men who have sex with men (MSM) and transgender women (TGW) provides critical insights to guide and optimise future roll-out of the PrEP in India.
methodsBetween 18 December 2019 and 31 July 2023, self-identified MSM and TGW, ≥18 years, at substantial risk for HIV were followed for 12 months for PrEP acceptability, adherence, adverse events and condom use at community-based and clinic-based settings in Jalandhar (Punjab) and Pune (Maharashtra), respectively. Data were analysed for correlates of retention and adherence. Exit interviews were conducted.
resultsThe median (IQR) age of the 650 participants was 26 (22, 30) years; the majority were literate and unmarried. The overall 1-year retention was 63.2%, with 84% and 41.7% in the community-based and clinic-based settings respectively. Overall, 64.8% participants had ≥80% adherence. Being from a community-based setting, having received secondary/higher secondary/graduate level education and living with family were significantly associated with ≥80% adherence. Overall, 9.7% showed grade-2 decline in creatinine clearance. Among 411 retained, condomless anal sex (CAS) with any partner, anytime in the last 6 months was 84.4% and 78.1% at baseline and 12 months respectively. Overall, seven seroconversions occurred.
conclusionDaily oral PrEP was acceptable and safe among MSM and TGW. Inclusion of PrEP as an additional prevention option would be critical for controlling HIV. Baseline risk assessment is important before initiating PrEP. Recurrent condom and risk reduction counselling during oral PrEP uptake is crucial for preventing CAS. Self-risk assessment and planned usage/stoppage of PrEP observed in the study indicates a need for counselling and assessment for potential interruptions of daily oral PrEP. Additionally, adherence would be affected, with implications for evaluating the programme's success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.